熱門資訊> 正文
Hemogenyx Pharmaceuticals to issue convertible loan notes
2025-09-02 16:03
- Hemogenyx Pharmaceuticals (OTCPK:HOPHF) issued convertible loan notes as the company continues the clinical trial of HG-CT-1, its CAR-T cell therapy for relapsed or refractory acute myeloid leukemia.
- The company was approached by a small investor group offering to provide funding to support the ongoing clinical trial.
- To support the clinical trial, the company has raised £620,000 through the issuance of CLNs at a fixed conversion price of £5.30 per share, being the closing share price on 29 August 2025.
- The CLNs, which are non-interest bearing, will automatically convert following an increase in the company's headroom restrictions under the FCA's Prospectus Rules, allowing for the issuance of conversion shares without requiring an approved prospectus.
- This conversion is expected to take place on or after 15 November 2025.
More on Hemogenyx Pharmaceuticals
- Financial information for Hemogenyx Pharmaceuticals Plc
推薦文章
美股機會日報 | 凌晨3點！美聯儲將公佈1月貨幣政策會議紀要，納指期貨漲近0.5%；13F大曝光！巴菲特連續三季減持蘋果
美股機會日報 | 阿里發佈千問3.5！性能媲美Gemini 3；馬斯克稱Cybercab將於4月開始生產
港股周報 | 中國大模型「春節檔」打響！智譜周漲超138%；鉅虧超230億！美團周內重挫超10%
一周財經日曆 | 港美股迎「春節+總統日」雙假期！萬億零售巨頭沃爾瑪將發財報
從軟件到房地產，美國多板塊陷入AI恐慌拋售潮
Meta計劃為智能眼鏡添加人臉識別技術
危機四伏，市場卻似乎毫不在意
財報前瞻 | 英偉達Q4財報放榜在即！高盛、瑞銀預計將大超預期，兩大關鍵催化將帶來意外驚喜？
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
